Insulin degludec, marketed as Tresiba, has a varied price depending on factors like dosage, formulation, and whether a prescription is available through insurance or a discount program. Without insurance, a 10-mL vial of Tresiba FlexTouch, for example, can cost several hundred dollars [1].
How much does Tresiba cost with insurance?
Insurance coverage significantly impacts the out-of-pocket cost of insulin degludec. Many insurance plans offer coverage for Tresiba, but co-pays can still range from a few dollars to over $100 per prescription, depending on the specific plan's formulary and deductible requirements. Patients are advised to check with their insurance provider for precise cost details.
Can you get cheaper insulin degludec with discount programs?
Pharmaceutical manufacturers and third-party organizations offer savings cards and discount programs that can reduce the cost of insulin degludec. For instance, Novo Nordisk, the manufacturer of Tresiba, may provide savings cards that allow eligible patients to pay as little as $99 for a one-month supply [1]. Discount cards from pharmacies or other discount providers can also offer savings.
What is the difference between Tresiba and other insulins?
Insulin degludec is a long-acting basal insulin with an ultra-long duration of action, lasting more than 24 hours. This profile allows for flexible dosing times. It differs from other basal insulins like insulin glargine (Lantus, Basaglar, Toujeo) and insulin detemir (Levemir) in its pharmacokinetic and pharmacodynamic properties, including its ultra-long duration and reduced pharmacokinetic variability [2]. Rapid-acting insulins, such as insulin lispro (Humalog), insulin aspart (NovoLog), and insulin glulisine (Apidra), are used to control blood sugar spikes after meals and have much shorter durations of action.
When does the patent for insulin degludec expire?
Patent information for pharmaceutical products, including insulin degludec, is complex and can involve multiple patents covering different aspects of the drug, such as the molecule itself, its formulation, and its method of use. DrugPatentWatch.com tracks these patents and their expiry dates, which are crucial for understanding when generic versions might become available [3]. Specific patent expiry dates can be found on specialized patent tracking websites.
What are the risks or side effects of insulin degludec?
Common side effects of insulin degludec include hypoglycemia (low blood sugar), allergic reactions, injection site reactions (redness, pain, itching), and lipodystrophy (changes in fat tissue at injection sites) [4]. More serious risks include severe hypoglycemia, which can be life-threatening, and potential fluid retention and heart failure, especially when used in combination with certain other diabetes medications like thiazolidinediones. Patients with diabetic ketoacidosis should not use insulin degludec.
What clinical data supports insulin degludec's effectiveness?
Clinical trials have demonstrated the efficacy and safety of insulin degludec in managing type 1 and type 2 diabetes. Studies have shown that it effectively lowers hemoglobin A1c (HbA1c) levels and reduces the risk of hypoglycemia compared to other basal insulins. For example, in trials for type 2 diabetes, Tresiba demonstrated non-inferiority in HbA1c reduction and a significantly lower rate of nocturnal hypoglycemia compared to insulin glargine U100 [5].
How is insulin degludec administered?
Insulin degludec is administered via subcutaneous injection. It is typically injected once daily into the abdomen, thigh, or upper arm. The flexibility in dosing time is a key feature, meaning it can be taken at any time of day, but a consistent daily time is recommended [6]. It is available in pre-filled pens, such as the Tresiba FlexTouch pen, and in vials.
Are there any alternatives to insulin degludec?
Besides other long-acting basal insulins like insulin glargine and insulin detemir, alternatives for diabetes management include other types of insulin (rapid-acting, intermediate-acting, premixed insulins), non-insulin injectable medications (GLP-1 receptor agonists), and oral antidiabetic agents. The choice of treatment depends on individual patient needs, disease severity, and other medical conditions.
Sources:
[1] https://www.goodrx.com/tresiba
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407821
[3] https://drugpatentwatch.com/
[4] https://www.tresiba.com/safety-information
[5] https://www.nejm.org/doi/full/10.1056/NEJMoa1208499
[6] https://www.tresiba.com/how-to-use